Overview

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, and efficacy of three different doses of NBI-921352 versus placebo in adults with focal onset seizures
Phase:
Phase 2
Details
Lead Sponsor:
Neurocrine Biosciences